Analysts Have Conflicting Sentiments on These Healthcare Companies: Fresenius Medical Care (FMS), BridgeBio Pharma (BBIO) and Globus Medical (GMED)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fresenius Medical Care (FMS – Research Report), BridgeBio Pharma (BBIO – Research Report) and Globus Medical (GMED – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fresenius Medical Care (FMS)
Truist Financial analyst David S Macdonald maintained a Hold rating on Fresenius Medical Care today. The company’s shares closed last Tuesday at $22.66.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Fresenius Medical Care.
See the top stocks recommended by analysts >>
BridgeBio Pharma (BBIO)
In a report released today, Danielle Brill from Truist Financial reiterated a Buy rating on BridgeBio Pharma, with a price target of $95.00. The company’s shares closed last Tuesday at $68.31.
According to TipRanks.com, Brill is a 4-star analyst with an average return of
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $101.56, which is a 49.6% upside from current levels. In a report issued on February 12, TD Cowen also maintained a Buy rating on the stock with a $95.00 price target.
Globus Medical (GMED)
In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Globus Medical, with a price target of $115.00. The company’s shares closed last Tuesday at $91.88, close to its 52-week high of $94.93.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Globus Medical has an analyst consensus of Strong Buy, with a price target consensus of $107.92, which is a 14.6% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $123.00 price target.
